KR20190088740A - Antioxidant and anti-Obesity composition comprising Psyllium Husk and Kaempferia parviflora, formulatiom using the composition and preparing method thereof - Google Patents
Antioxidant and anti-Obesity composition comprising Psyllium Husk and Kaempferia parviflora, formulatiom using the composition and preparing method thereof Download PDFInfo
- Publication number
- KR20190088740A KR20190088740A KR1020180007205A KR20180007205A KR20190088740A KR 20190088740 A KR20190088740 A KR 20190088740A KR 1020180007205 A KR1020180007205 A KR 1020180007205A KR 20180007205 A KR20180007205 A KR 20180007205A KR 20190088740 A KR20190088740 A KR 20190088740A
- Authority
- KR
- South Korea
- Prior art keywords
- powder
- weight
- parts
- lactobacillus
- antioxidant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 49
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 39
- 230000003579 anti-obesity Effects 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims description 9
- 241000395050 Kaempferia parviflora Species 0.000 title description 2
- 244000134552 Plantago ovata Species 0.000 title description 2
- 235000003421 Plantago ovata Nutrition 0.000 title description 2
- 239000009223 Psyllium Substances 0.000 title description 2
- 239000010903 husk Substances 0.000 title description 2
- 229940070687 psyllium Drugs 0.000 title description 2
- 239000000843 powder Substances 0.000 claims abstract description 60
- 241000234314 Zingiber Species 0.000 claims abstract description 26
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 26
- 235000008397 ginger Nutrition 0.000 claims abstract description 26
- 244000269722 Thea sinensis Species 0.000 claims abstract description 17
- 239000000883 anti-obesity agent Substances 0.000 claims abstract description 5
- 229940125710 antiobesity agent Drugs 0.000 claims abstract description 5
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims description 16
- 235000013311 vegetables Nutrition 0.000 claims description 15
- 239000006041 probiotic Substances 0.000 claims description 13
- 235000018291 probiotics Nutrition 0.000 claims description 13
- 241000186660 Lactobacillus Species 0.000 claims description 12
- 229940039696 lactobacillus Drugs 0.000 claims description 12
- 235000013616 tea Nutrition 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 244000228451 Stevia rebaudiana Species 0.000 claims description 10
- 239000003651 drinking water Substances 0.000 claims description 9
- 235000020188 drinking water Nutrition 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 229940094952 green tea extract Drugs 0.000 claims description 8
- 235000020688 green tea extract Nutrition 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 229940069521 aloe extract Drugs 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 239000004382 Amylase Substances 0.000 claims description 6
- 102000013142 Amylases Human genes 0.000 claims description 6
- 108010065511 Amylases Proteins 0.000 claims description 6
- 229920002774 Maltodextrin Polymers 0.000 claims description 6
- 239000005913 Maltodextrin Substances 0.000 claims description 6
- 108091005804 Peptidases Proteins 0.000 claims description 6
- 239000004365 Protease Substances 0.000 claims description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 6
- 235000019418 amylase Nutrition 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 229940035034 maltodextrin Drugs 0.000 claims description 6
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 5
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 5
- 244000141353 Prunus domestica Species 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 5
- 235000013325 dietary fiber Nutrition 0.000 claims description 5
- 235000001727 glucose Nutrition 0.000 claims description 5
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 3
- 241000186012 Bifidobacterium breve Species 0.000 claims description 3
- 244000199866 Lactobacillus casei Species 0.000 claims description 3
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 3
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 3
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 3
- 229940017800 lactobacillus casei Drugs 0.000 claims description 3
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 3
- 241001608472 Bifidobacterium longum Species 0.000 claims description 2
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 2
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 2
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 230000002292 Radical scavenging effect Effects 0.000 abstract description 21
- 210000000577 adipose tissue Anatomy 0.000 abstract description 17
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 abstract description 12
- 229930003935 flavonoid Natural products 0.000 abstract description 11
- 235000017173 flavonoids Nutrition 0.000 abstract description 11
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 abstract description 10
- 235000013824 polyphenols Nutrition 0.000 abstract description 9
- 150000008442 polyphenolic compounds Chemical class 0.000 abstract description 7
- 210000000579 abdominal fat Anatomy 0.000 abstract description 6
- 150000002215 flavonoids Chemical class 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 235000006708 antioxidants Nutrition 0.000 description 34
- -1 mucus Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 14
- 208000008589 Obesity Diseases 0.000 description 13
- 235000020824 obesity Nutrition 0.000 description 13
- 235000011399 aloe vera Nutrition 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 241001116389 Aloe Species 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- 230000037396 body weight Effects 0.000 description 8
- JRFZSUMZAUHNSL-UHFFFAOYSA-N chrysin 5,7-dimethyl ether Chemical compound C=1C(OC)=CC(OC)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 JRFZSUMZAUHNSL-UHFFFAOYSA-N 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 230000007423 decrease Effects 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 241000544066 Stevia Species 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 235000019202 steviosides Nutrition 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 229940013618 stevioside Drugs 0.000 description 5
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 5
- IAFBOKYTDSDNHV-UHFFFAOYSA-N (2S)-(-)-5,7-dimethoxyflavanone Natural products O1C2=CC(OC)=CC(OC)=C2C(=O)CC1C1=CC=CC=C1 IAFBOKYTDSDNHV-UHFFFAOYSA-N 0.000 description 4
- ZXJJBDHPUHUUHD-UHFFFAOYSA-N 4',5,7-Trimethoxyflavone Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C=C(OC)C=C2O1 ZXJJBDHPUHUUHD-UHFFFAOYSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 4
- 150000004056 anthraquinones Chemical class 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- CBTHKWVPSIGKMI-UHFFFAOYSA-N galangin 3,5,7-trimethyl ether Chemical compound C=1C(OC)=CC(OC)=C(C(C=2OC)=O)C=1OC=2C1=CC=CC=C1 CBTHKWVPSIGKMI-UHFFFAOYSA-N 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 229940002508 ginger extract Drugs 0.000 description 4
- 235000020708 ginger extract Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- IRZVHDLBAYNPCT-UHFFFAOYSA-N tectochrysin Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 IRZVHDLBAYNPCT-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 210000003486 adipose tissue brown Anatomy 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 235000009569 green tea Nutrition 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- ALGDHWVALRSLBT-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-3,5,7-trimethoxychromen-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 ALGDHWVALRSLBT-UHFFFAOYSA-N 0.000 description 2
- YZWIIEJLESXODL-UHFFFAOYSA-N 3,5,7-trimethoxy-2-(4-methoxyphenyl)chromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C=C(OC)C=C2O1 YZWIIEJLESXODL-UHFFFAOYSA-N 0.000 description 2
- KQNCAPDRHYRSCV-UHFFFAOYSA-N 3,5,7-trimethoxyflavone Natural products COC1=C(OC2=CC(=C(C=C2C1=O)OC)OC)C1=CC=CC=C1 KQNCAPDRHYRSCV-UHFFFAOYSA-N 0.000 description 2
- ZAIANDVQAMEDFL-UHFFFAOYSA-N 3-methoxy-2-phenylchromen-4-one Chemical class O1C2=CC=CC=C2C(=O)C(OC)=C1C1=CC=CC=C1 ZAIANDVQAMEDFL-UHFFFAOYSA-N 0.000 description 2
- LJJZKMDEQVYRJX-UHFFFAOYSA-N 4,5,6-tripyridin-2-yltriazine Chemical compound N1=CC=CC=C1C1=NN=NC(C=2N=CC=CC=2)=C1C1=CC=CC=N1 LJJZKMDEQVYRJX-UHFFFAOYSA-N 0.000 description 2
- OYCOUDKDRFJOCP-UHFFFAOYSA-N 5-hydroxy-3,7-dimethoxy-2-phenylchromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=CC=C1 OYCOUDKDRFJOCP-UHFFFAOYSA-N 0.000 description 2
- 244000144927 Aloe barbadensis Species 0.000 description 2
- 235000002961 Aloe barbadensis Nutrition 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 2
- 235000017491 Bambusa tulda Nutrition 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 2
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 2
- 235000003805 Musa ABB Group Nutrition 0.000 description 2
- 240000008790 Musa x paradisiaca Species 0.000 description 2
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 2
- 244000082204 Phyllostachys viridis Species 0.000 description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 2
- 235000015266 Plantago major Nutrition 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 108010041191 Sirtuin 1 Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- JGDITNMASUZKPW-UHFFFAOYSA-K aluminium trichloride hexahydrate Chemical compound O.O.O.O.O.O.Cl[Al](Cl)Cl JGDITNMASUZKPW-UHFFFAOYSA-K 0.000 description 2
- 239000011425 bamboo Substances 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 244000000074 intestinal pathogen Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- CKEXCBVNKRHAMX-UHFFFAOYSA-N (-)-naringenin 4',7-dimethyl ether Natural products C1=CC(OC)=CC=C1C1OC2=CC(OC)=CC(O)=C2C(=O)C1 CKEXCBVNKRHAMX-UHFFFAOYSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- KMVWNDHKTPHDMT-UHFFFAOYSA-N 2,4,6-tripyridin-2-yl-1,3,5-triazine Chemical compound N1=CC=CC=C1C1=NC(C=2N=CC=CC=2)=NC(C=2N=CC=CC=2)=N1 KMVWNDHKTPHDMT-UHFFFAOYSA-N 0.000 description 1
- BDNFUEHBPAAYSS-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-3,5,7-trimethoxychromen-4-one Chemical compound COC1=C(OC2=CC(=CC(=C2C1=O)OC)OC)C1=CC(=C(C=C1)OC)OC.COC1=C(OC2=CC(=CC(=C2C1=O)OC)OC)C1=CC(=C(C=C1)OC)OC BDNFUEHBPAAYSS-UHFFFAOYSA-N 0.000 description 1
- WSQWAMGRHJQANC-UHFFFAOYSA-N 3,4',7-Trimethylkaempferol Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(O)C=C(OC)C=C2O1 WSQWAMGRHJQANC-UHFFFAOYSA-N 0.000 description 1
- TXVLBOXMGWKLEM-UHFFFAOYSA-N 3,5,7-trimethoxy-2-(4-methoxyphenyl)chromen-4-one Chemical compound COC1=C(OC2=CC(=CC(=C2C1=O)OC)OC)C1=CC=C(C=C1)OC.COC1=C(OC2=CC(=CC(=C2C1=O)OC)OC)C1=CC=C(C=C1)OC TXVLBOXMGWKLEM-UHFFFAOYSA-N 0.000 description 1
- MJWUIOHNTXYHBI-UHFFFAOYSA-N 3,7-dimethylgalangin Natural products COC1=C(C(=O)c2cc(OC)cc(O)c2C1=O)c3ccccc3 MJWUIOHNTXYHBI-UHFFFAOYSA-N 0.000 description 1
- HHGPYJLEJGNWJA-UHFFFAOYSA-N 5-hydroxy-3,3',4',7-tetramethoxyflavone Chemical compound C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HHGPYJLEJGNWJA-UHFFFAOYSA-N 0.000 description 1
- NYYMNZLORMNCKK-UHFFFAOYSA-N 5-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1O NYYMNZLORMNCKK-UHFFFAOYSA-N 0.000 description 1
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 1
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- AFHJQYHRLPMKHU-XXWVOBANSA-N Aloin Natural products O=C1c2c(O)cc(CO)cc2[C@H]([C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)c2c1c(O)ccc2 AFHJQYHRLPMKHU-XXWVOBANSA-N 0.000 description 1
- 240000002768 Alpinia galanga Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 206010051548 Burn infection Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- SSYQGPQWRNLGNB-UHFFFAOYSA-N OC1=C2C(C(=C(OC2=CC(=C1)OC)C1=CC(=C(C=C1)OC)OC)OC)=O.OC1=C2C(C(=C(OC2=CC(=C1)OC)C1=CC(=C(C=C1)OC)OC)OC)=O Chemical compound OC1=C2C(C(=C(OC2=CC(=C1)OC)C1=CC(=C(C=C1)OC)OC)OC)=O.OC1=C2C(C(=C(OC2=CC(=C1)OC)C1=CC(=C(C=C1)OC)OC)OC)=O SSYQGPQWRNLGNB-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- GXAPLLMJHZBIPX-UHFFFAOYSA-N Retusine Natural products O1C(=O)C(C)C(C)C(C)(O)C(=O)OCC2CCN3C2C1CC3 GXAPLLMJHZBIPX-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- QFVOYBUQQBFCRH-UHFFFAOYSA-N Steviol Natural products C1CC2(C3)CC(=C)C3(O)CCC2C2(C)C1C(C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-UHFFFAOYSA-N 0.000 description 1
- 239000004383 Steviol glycoside Substances 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- ZTOJFFHGPLIVKC-CLFAGFIQSA-N abts Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- CPUHNROBVJNNPW-UHFFFAOYSA-N aloin A Natural products OC1C(O)C(O)C(CO)OC1OC1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 CPUHNROBVJNNPW-UHFFFAOYSA-N 0.000 description 1
- AFHJQYHRLPMKHU-WEZNYRQKSA-N aloin B Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@H]1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-WEZNYRQKSA-N 0.000 description 1
- 229940009861 aluminum chloride hexahydrate Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- LZERJKGWTQYMBB-UHFFFAOYSA-N apigenin 7,4'-dimethyl ether Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OC)C=C2O1 LZERJKGWTQYMBB-UHFFFAOYSA-N 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- RJWJHRPNHPHBRN-FKVJWERZSA-N aucubin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(CO)=C[C@@H](O)[C@@H]2C=CO1 RJWJHRPNHPHBRN-FKVJWERZSA-N 0.000 description 1
- UTDFQMAXCUGNJR-UHFFFAOYSA-N aucubin Natural products OCC1OC(Oc2ccoc2C3C(O)CCC3O)C(O)C(O)C1O UTDFQMAXCUGNJR-UHFFFAOYSA-N 0.000 description 1
- OHDRQQURAXLVGJ-AXMZSLBLSA-N azane;(2z)-3-ethyl-2-[(z)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-AXMZSLBLSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 150000004687 hexahydrates Chemical class 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- WVLDCUJMGWFHGE-UHFFFAOYSA-L iron(2+);sulfate;hexahydrate Chemical compound O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O WVLDCUJMGWFHGE-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- AFHJQYHRLPMKHU-UHFFFAOYSA-N isobarbaloin Natural products OC1C(O)C(O)C(CO)OC1C1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-UHFFFAOYSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 238000011623 obesity animal model Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 229930182496 polymethoxyflavone Natural products 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- QFVOYBUQQBFCRH-VQSWZGCSSA-N steviol Chemical compound C([C@@]1(O)C(=C)C[C@@]2(C1)CC1)C[C@H]2[C@@]2(C)[C@H]1[C@](C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-VQSWZGCSSA-N 0.000 description 1
- 229940032084 steviol Drugs 0.000 description 1
- 229930182488 steviol glycoside Natural products 0.000 description 1
- 235000019411 steviol glycoside Nutrition 0.000 description 1
- 150000008144 steviol glycosides Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000019722 synbiotics Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 차전차피 분말 50~70중량부 및 흑생강 분말 5~20중량부를 포함하는 항산화 및 항비만 조성물, 이를 과립화한 항산화 및 항비만 제제 및 이의 제조방법에 관한 것으로, 본 발명의 조성물은 천연성분인 차전차피 분말과 흑생강 분말을 사용하여 제조함으로써 폴리페놀 함량, 플라보노이드 함량, DPPH 라디칼 소거활성, ABTS 라디칼 소거활성 및 환원력으로 확인된 항산화효과가 우수하며, 인체에 섭취시켰을 때 체중, 체질량지수, 체지방, 체지방율 및 복부지방율의 감소로 확인된 항비만효과가 우수하다. The present invention relates to an antioxidant and anti-obesity composition comprising 50 to 70 parts by weight of powdered tea powder and 5 to 20 parts by weight of a black ginger powder, an antioxidant and anti-obesity agent granulated with the composition and a method for producing the same, Is excellent in antioxidative effect as confirmed by polyphenol content, flavonoid content, DPPH radical scavenging activity, ABTS radical scavenging activity and reducing power when it is prepared by using the natural tea component powder and black ginger powder, , Body mass index, body fat, body fat percentage, and abdominal fat ratio.
Description
본 발명은 차전차피와 흑생강을 유효성분으로 함유하는 항산화 및 항비만 조성물, 이를 과립화한 항산화 및 항비만 제제 및 이의 제조방법에 관한 것이다.The present invention relates to an antioxidant and anti-obesity composition containing tea tramp blood and black ginger as active ingredients, an antioxidant and an anti-obesity agent granulated with the composition, and a process for producing the same.
우리나라는 물론 세계적으로 경제발전 및 의료기술의 발달로 인하여 인간의 평균수명이 길어지고 삶의 질이 빠른 속도로 향상되고 있어 이에 부합하는 적극적인 웰빙시대의 대응전략이 시급히 요청되고 있다. 특히, 가속화되고 있는 노령화, 성인병의 발생에 따른 국민건강의 보호 및 정부와 개인의 의료비 절감의 차원에서도 효과적이고 안전한 관련 건강기능식품의 개발이 필요하다. Since the life expectancy of human beings has been lengthened and the quality of life has been rapidly improved due to the development of economic development and medical technology in the world as well as in Korea, there is a urgent need for an aggressive wellbeing response strategy corresponding to this. Especially, it is necessary to develop effective and safe related health functional foods in the dimension of accelerating aging, protection of the public health due to the occurrence of adult diseases, and reduction of the government and individual medical expenses.
심장마비, 고혈압, 동맥경화, 뇌졸중 등의 심혈관질환은 세계적으로 전체 사망률의 30%를 차지하고 있다. 특히 비만, 당뇨병, 고혈압, 동맥경화증, 심장 질환, 뇌졸중 등은 각기 다른 질병으로 보이지만 체지방 증가로 인한 인슐린 저항성이라는 공통 병인을 갖는 하나의 증후군으로 이해되고 있다.Cardiovascular diseases such as heart attack, hypertension, arteriosclerosis and stroke account for 30% of the total mortality worldwide. In particular, obesity, diabetes, hypertension, atherosclerosis, heart disease, and stroke are seen as different diseases, but they are understood as a syndrome with a common cause of insulin resistance due to increased body fat.
비만은 전 세계적으로 가장 흔한 영양장애 중의 하나로서 WHO 통계자료에 의하면 현재 2억 5천여만명이 비만 환자로 분류되며 20년 후에는 약 3억명이 비만으로 고통받을 것으로 예측된다. Obesity is one of the most common malnutrition disorders worldwide. According to WHO statistics, 250 million people are currently classified as obese, and after 20 years about 300 million people are expected to suffer from obesity.
비만은 비만 자체보다는 비만으로 인하여 유발되는 관련 질병이 큰 문제가 되고 있다. 일반적으로 비만인 사람은 정상인보다 동맥경화는 4배, 당뇨병은 2배, 고혈압은 3배, 심장질환은 3배 높은 발생위험을 가지고 있다. 비만도가 높을수록 당뇨병, 담석증, 고혈압, 심장질환, 뇌졸중 등의 대사증후군 유병율이 증가되므로 비만으로 인해 야기되는 경제적 부담과 인명적 손실이 막대하며 큰 사회적 문제가 되고 있다.Obesity is a major problem in obesity-related diseases caused by obesity rather than obesity itself. In general, obese people are at risk of developing atherosclerosis 4 times, diabetes 2 times, hypertension 3 times, and heart disease 3 times higher than normal people. The higher the degree of obesity, the higher the prevalence of metabolic syndrome such as diabetes, cholelithiasis, hypertension, heart disease, stroke, etc., resulting in a great economic and social loss caused by obesity.
미국에서 행해진 역학조사결과에 의하면 1991년 비만과 관련된 질병에 의한 사망자가 280,000명이며, 이들의 약 80%가 BMI>30인 고도비만자이고, 한해에 약 120조원이 비만 관련 질환치료에 소모된 것으로 보고되고 있다. According to epidemiological studies conducted in the US, about 280,000 deaths from obesity-related illnesses in 1991, about 80% of them were obese at a BMI> 30, and about 120 trillion won a year were spent on treating obesity-related diseases Are reported.
현재 변비 개선 및 체지방 감량과 관련된 다양한 종류의 제품들이 국내외에서 개발되어 있는데 이들은 주로 식이섬유를 주원료로 하고 있다.Currently, a variety of products related to constipation improvement and body fat reduction have been developed at home and abroad, mainly based on dietary fiber.
본 발명은 천연성분인 차전차피와 흑생강을 사용하여 항산화 효과가 우수하고 체중 및 체지방감량효과가 우수한 항산화 및 항비만 조성물을 제공하는 것을 목적으로 한다. It is an object of the present invention to provide an antioxidant and anti-obesity composition which is excellent in antioxidative effect and excellent in body weight and body fat loss effect by using tea root oil and black ginger which are natural ingredients.
상기 목적을 달성하기 위하여, In order to achieve the above object,
본 발명은 차전차피 분말 50~70중량부 및 흑생강 분말 5~20중량부를 포함하는 항산화 및 항비만 조성물을 제공한다. 상기 조성물은 바람직하게는 차전차피 분말 55~65중량부 및 흑생강 분말 7~14중량부를 포함한다. 상기 조성물에서, 상기 차전차피 분말은 식이섬유의 함량이 80% 이상인 것이 바람직하다.The present invention provides an antioxidant and anti-obesity composition comprising 50 to 70 parts by weight of powdered tea powder and 5 to 20 parts by weight of black ginger powder. The composition preferably contains 55 to 65 parts by weight of the tea powder powder and 7 to 14 parts by weight of the black ginger powder. In the composition, it is preferable that the content of the dietary fiber in the powdery powder is 80% or more.
상기 조성물은, 녹차추출물 분말, 알로에추출물 분말, 프룬농축분말, 프로바이오틱스 중에서 선택된 1종 또는 2종 이상의 추가성분 0.5~20중량부를 더 포함할 수 있다.The composition may further comprise 0.5 to 20 parts by weight of one or more additional components selected from green tea extract powder, aloe extract powder, prune concentrated powder and probiotics.
상기 조성물은, 분말결정포도당, 아밀라아제, 식물성 프로테아제, 효소처리스테비아, 식물성 크림분말 및 말토덱스트린 중에서 선택된 1종 또는 2종 이상의 첨가제 0.5~20중량부를 더 포함할 수 있다.The composition may further comprise 0.5-20 parts by weight of one or more additives selected from powdered crystalline glucose, amylase, vegetable protease, enzyme-treated stevia, vegetable cream powder and maltodextrin.
또한, 본 발명은 상기 항산화 및 항비만 조성물을 과립형태로 제제화한 과립형 항산화 및 항비만 제제를 제공한다.The present invention also provides granular antioxidant and anti-obesity preparations in which the antioxidant and anti-obesity composition is formulated in the form of granules.
또한, 본 발명은 In addition,
(a) 차전차피 분말 50~70중량부와 흑생강 분말 5~20중량부를 포함하는 주원료, (b) 녹차추출물 분말; 알로에추출물 분말; 프룬농축분말; 프로바이오틱스 중에서 선택된 1종 또는 2종 이상의 추가성분 0.5~20중량부, 그리고 (c) 분말결정포도당, 아밀라아제, 식물성 프로테아제, 효소처리스테비아, 식물성 크림분말 및 말토덱스트린 중에서 선택된 1종 또는 2종 이상의 첨가제 0.5~20중량부 각각의 원료를 체로 쳐서 균일화하는 단계;(a) an active ingredient comprising 50 to 70 parts by weight of the powdery powder and 5 to 20 parts by weight of black ginger powder; (b) a green tea extract powder; Aloe extract powder; Prune-concentrated powder; 0.5 to 20 parts by weight of one or more additional components selected from probiotics and (c) one or more additives selected from powdered crystalline glucose, amylase, vegetable protease, enzyme-treated stevia, vegetable cream powder and maltodextrin 0.5 To 20 parts by weight of a raw material;
상기 균일화된 각 원료를 혼합하는 단계;Mixing each of the homogenized raw materials;
상기 원료의 혼합물에 혼합물 100중량부 당 음용수 1~100 중량부를 가하여 혼합하는 단계;Adding 1 to 100 parts by weight of drinking water per 100 parts by weight of the mixture to the mixture of the raw materials;
상기 원료와 음용수의 혼합물을 과립화하는 단계; 및Granulating a mixture of the raw material and the drinking water; And
상기 과립을 60±2℃에서 수분함량이 10% 이하가 되도록 건조시키는 단계를 포함하는 과립형 항산화 및 항비만 제제의 제조방법을 제공한다.And drying the granules so that the water content is not more than 10% at 60 占 占 폚. The present invention also provides a method for producing granular antioxidant and anti-obesity agents.
본 발명의 항산화 및 항비만 조성물은 천연성분인 차전차피 분말과 흑생강 분말을 사용하여 제조함으로써 폴리페놀 함량, 플라보노이드 함량, DPPH 라디칼 소거활성, ABTS 라디칼 소거활성 및 환원력으로 확인된 항산화효과가 우수하며, 인체에 섭취시켰을 때 체중, 체질량지수, 체지방, 체지방율 및 복부지방율의 감소로 확인된 항비만효과가 우수하다. 또한 천연성분을 사용하여 인체에 해가 없으므로, 다이어트용 건강보조식품으로 유용하게 사용할 수 있다. The antioxidant and anti-obesity composition of the present invention has excellent antioxidative effect as confirmed by polyphenol content, flavonoid content, DPPH radical scavenging activity, ABTS radical scavenging activity and reducing power, by using a natural tea component powder and black ginger powder , And the anti-obesity effect confirmed by the decrease in body weight, body mass index, body fat, body fat percentage and abdominal fat percentage when the human body is ingested is excellent. Also, because it is harmless to human body by using natural ingredients, it can be useful as a dietary supplement.
도 1은 본 발명의 과립형 항산화 및 항비만 제제의 사진이다. Figure 1 is a photograph of the granular antioxidant and anti-obesity agent of the present invention.
본 발명의 항산화 및 항비만 조성물은 차전차피 분말 50~70중량부 및 흑생강 분말 5~20중량부를 포함한다. 바람직하게는 차전차피 분말 55~65중량부 및 흑생강 분말 7~14중량부를 포함한다.The antioxidant and anti-obesity composition of the present invention comprises 50 to 70 parts by weight of powdery powder and 5 to 20 parts by weight of black ginger powder. Preferably 55 to 65 parts by weight of the tea powder powder and 7 to 14 parts by weight of the black ginger powder.
차전자피(Psyllium Husk)는 질경이 씨의 껍질로써 전국 각지의 들이나 길가에 자생하고 있다. 차전차피는 점액을 형성하는 아라비녹실란-다당류(arabinoxylan-polysaccharide)를 다량 함유하여 수분 보유량이 뛰어난 식품으로 장의 숙변 제거에 효과적인데, 이는 질경이에 있는 헤미셀룰로오스(hemicellulose) 성분의 반수용성 섬유소가 대장 내에서 자체 중량의 40배 이상의 많은 수분을 흡수함으로써 부피가 팽창하여 장벽에 붙은 불순물 및 숙변을 배설하게 하고 장관벽에 작용하여 장의 연동운동을 촉진시키는 것으로 알려져 있다. 차전차피의 주요 성분은 다량의 점액질, 지방질, 아우쿠빈(aucubin), 갈락탄(galactan), 다당류, 숙신산(succinic acid) 등의 식이섬유소원으로 대부분 생체 내 소화효소에 의해 가수분해되지 않는 난소화성으로 장내세균에 의해 이용되고 에너지 열량이 낮아 저칼로리 식품소재로서 주목받고 있다. 차전차피의 효과로는 혈청 총 콜레스테롤 농도 저하, LDL 콜레스테롤 농도 저하, 중성지질 농도 저하, 사염화탄소 유발 실험적 간독성에 대한 해독, 제2형 당뇨병 환자의 총 콜레스테롤 농도 저하, 만성 퇴행성 질환에 대한 예방 및 치료효과 등이 보고되어 있다. 본 발명의 조성물에서 차전차피 분말은 식이섬유의 함량이 80% 이상인 것을 사용하는 것이 바람직하다.Psyllium Husk is a bark of seeds of plantain, which grows naturally throughout the country. It is effective for the removal of the intestinal tract of the intestinal tract because it contains a large amount of arabinoxylan-polysaccharide which forms mucus, which is excellent in moisture retention. This is because hemicellulose half-water soluble fiber in the plantain It absorbs much moisture more than 40 times its own weight, and it is known that it expands in volume to excrete impurities and succulents attached to the barrier and acts on the intestinal wall to promote peristaltic movement of the intestines. The major components of tea tram blooms are dietary fibrinolytic substances such as mucus, fat, aucubin, galactan, polysaccharide and succinic acid, which are mostly hydrolyzed by in vivo digestive enzymes. It has been attracting attention as a low-calorie food material because it is used by intestinal bacteria and has a low energy calorie. The effect of tea tramp blood was evaluated as a decrease in serum total cholesterol concentration, a decrease in LDL cholesterol concentration, a decrease in neutral lipid concentration, a decline in experimental hepatotoxicity caused by carbon tetrachloride, a decrease in total cholesterol concentration in type 2 diabetic patients, Have been reported. In the composition of the present invention, it is preferable to use a powder having a dietary fiber content of 80% or more.
흑생강(Kaempferia parviflora)은 생강과(Zingiberaceae)와 강황(Turmeric)에 속하기도 하며, 태국어로 끄라차이담(KraChaDum)으로 알려져 있다. 전 세계에 대략 60여 종이 있는 것으로 알려져 있으며 동남아지역 라오스, 태국, 인도차이나반도에서 주로 재배하는 식물로 전통의 약재소재로 많은 연구가 진행되고 있으며, 뿌리줄기 부분은 동남아시아에서 전통적인 민간 의약품으로 사용되고 있다. 흑생강은 항산화, 항염, 위장 보호, 남성 성기능 개선, 항말라리아, 항바이러스, 항박테리아, 항암, 항알러지, 항비만, 복부불편함 완화 등 통증완화작용 등의 다양한 생리활성을 나타내는 것으로 알려져 있다. 특히 항비만 효과에 있어 ob/ob 비만 동물모델에서 흑생강 표준추출물(KPE)과 이의 기능성분인 DMF(5,7-dimethoxyflavone)가 실험동물의 식욕에는 영향을 주지 않고 체중, 지방 부피 및 지방 무게를 유의하게 감소시켰으며 부고환지방조직에서 AMPK(AMP-activated protein kinase)를 활성화시킴으로써 지방 생성 관련 전사인자와 지질 생성 관련 효소의 발현을 억제하고 콜레스테롤 혈증 및 비알콜성 지방간의 증상을 감소시킨 것으로 보고되고 있다. 또한 근육섬유의 크기, 근육의 부피 및 근육의 무게를 현저히 증가시키고, 이로 인해 지구력 및 근력과 같은 근육의 기능을 향상시키는 것으로 보고되고 있다. 27마리의 마우스에 흑생강 추출물을 투여한 결과 체중과 내장지방이 유의적으로 감소하였고, 흑생강 에탄올 추출물의 섭취시(100mg/day) 건강한 사람에 있어 갈색지방조직(brown adipose tissue)의 활성을 증가시켜 전체 에너지 소비량을 증가시키는 것으로 보고되었다. 흑생강 추출물의 비만억제 메커니즘은 갈색지방조직에서 UCP1(uncoupling protein 1)의 발현을 증가시켜 갈색지방조직의 활성화에 의한 에너지 신진대사를 촉진시키는 것으로 확인되었다. 또한 100㎍/㎖의 흑생강 추출물은 레즈베라트롤보다 5배 높은 SIRT1의 활성을 나타내었다는 연구결과가 보고되어 있는데 SIRT1 효소는 장수 유전자로 노화와 함께 찾아오는 치매, 당뇨병, 비만과 운동장해와 같은 증상을 지연시켜 주는 유전자로 알려져 있다. 이외 흑생강의 에탄올 추출물은 쥐 실험모델에 있어 스트레스에 의해 유발된 위궤양 형성을 유의하게 억제하는 것으로 나타나 사람에 있어서도 효능이 있을 것으로 판단되고 있으며, 메톡시플라본(methoxyflavones)이 콜린에스테라제(cholinesterase) 저해효과가 있어 알츠하이머 치료제로서의 가능성도 제시되고 있다. Black ginger ( Kaempferia parviflora ) belongs to the ginger (Zingiberaceae) and Turmeric, also known as KraChaDum in Thai. It is known that there are about 60 species in the world. Plants cultivated mainly in Laos, Thailand and Indochina Peninsula in Southeast Asia are being studied as traditional medicinal materials. Roots are used as traditional traditional medicines in Southeast Asia . Black ginger is known to exhibit various physiological activities such as antioxidant, antiinflammatory, gastrointestinal protection, male sexual function improvement, anti-malaria, antiviral, antibacterial, anti-cancer, antiallergic, anti-obesity, pain relief such as abdominal discomfort relief. In particular, in the ob / ob obesity animal model, the standard extract of black ginger (KPE) and its functional component DMF (5,7-dimethoxyflavone) did not affect the appetite of the experimental animals, (AMP-activated protein kinase) was activated in epididymal adipose tissue to inhibit the expression of lipogenesis-related transcription factors and lipid-related enzymes and to reduce the symptoms of cholesterol and nonalcoholic fatty liver . It has also been reported to significantly increase muscle fiber size, muscle volume and muscle weight, thereby improving muscle function such as endurance and strength. The administration of black ginger extract to 27 mice significantly reduced body weight and visceral fat, and the activity of brown adipose tissue in healthy subjects at the time of ingestion of black ginger ethanol extract (100 mg / day) To increase total energy consumption. The mechanism of obesity inhibition of black ginger extract was found to promote the energy metabolism by the activation of brown adipose tissue by increasing the expression of UCP1 (uncoupling protein 1) in brown adipose tissue. In addition, studies have shown that 100 ㎍ / ㎖ of black ginger extract has a 5-fold higher activity of SIRT1 than that of resveratrol. SIRT1 enzyme is a long-lived gene that is associated with senescence, diabetes, obesity, It is known as a gene to delay symptoms. In addition, the ethanol extract of black ginger significantly inhibited stress-induced gastric ulcer formation in a rat model, indicating that methoxyflavones may be effective in humans, and cholinesterase (methoxyflavones) ), Which is a potential therapeutic drug for Alzheimer's.
흑생강의 주요성분으로는 폴리메톡시플라본으로 5,7-디메톡시 플라본 (5,7-dimethoxyflavone), 5,7,4'-트리메톡시플라본 (5,7,4'-trimethoxyflavone), 5,7,3',4'-테트라메톡시플라본 (5,7,3',4'-tetramethoxyflavone), 5-하이드록시-7-메톡시플라본 (5-hydroxy-7-methoxyflavone), 5-하이드록시-7,4'-디메톡시플라본 (5-hydroxy-7,4'-dimethoxyflavone), 5-하이드록시-3,7-디메톡시플라본 (5-hydroxy-3,7-dimethoxyflavone), 5-하이드록시-3,7,4'-트리메톡시플라본 (5-hydroxy-3,7,4' -trimethoxyflavone), 5-하이드록시-3,7,3',4'-테트라메톡시플라본 (5-hydroxy-3,7,3',4'-tetramethoxyflavone), 3,5,7-트리메톡시플라본 (3,5,7-trimethoxyflavone), 3,5,7,4'-테트라메톡시플라본 (3,5,7,4'-tetramethoxyflavone), 3,5,7,3',4'-펜타메톡시플라본 (3,5,7,3',4'-pentamethoxyflavone) 등이 보고되어 있다. The main ingredients of black ginger are 5,7-dimethoxyflavone, 5,7,4'-trimethoxyflavone, 5,7-dimethoxyflavone, , 5,3'4-tetramethoxyflavone, 5-hydroxy-7-methoxyflavone, 5-hydroxynaphthoic acid, Hydroxy-7,7-dimethoxyflavone, 5-hydroxy-3,7-dimethoxyflavone, 5-hydroxy- 5-hydroxy-3,7,4'-trimethoxyflavone, 5-hydroxy-3,7,3 ', 4'-tetramethoxy flavone (5- hydroxy-3,7,3 ', 4'-tetramethoxyflavone), 3,5,7-trimethoxyflavone, 3,5,7,4'-tetramethoxy flavone (3 , 5,7,4'-tetramethoxyflavone), 3,5,7,3 ', 4'-pentamethoxyflavone (3,5,7,3', 4'-pentamethoxyflavone) have been reported.
동물 연구에서 흑생강의 유효 용량은 체중 1kg 당 250-500mg이고 독성 데이터는 체중 1kg 당 최대 500mg의 투여량까지 안전하다고 보고되어 있으며 건강한 노인에 있어 8주간 90mg/일 섭취시 독성을 나타내지 않았고, 축구선수들에게 흑생강 추출물을 12주 동안 180mg/일의 용량으로 섭취시켰을 때 어떠한 부작용도 나타나지 않았으며 축구선수의 유산소능력(aerobic capacity)을 향상시켜 체력을 향상시키는 것으로 보고되었다. In animal studies, the effective dose of black ginger is 250-500 mg / kg body weight, and toxicity data are reported to be safe up to 500 mg dose per kg of body weight. In healthy elderly subjects, 90 mg / When the black ginger extract was taken at a dose of 180 mg / day for 12 weeks, the athlete showed no side effects and was reported to improve the aerobic capacity of soccer players.
본 발명의 조성물에서 흑생강(끄라이차담)은 태국산을 사용하는 것이 보다 바람직하다. In the composition of the present invention, it is more preferable to use Thai ginger (liquor).
본 발명의 조성물은 녹차추출물 분말, 알로에추출물 분말, 프룬농축분말, 프로바이오틱스 중에서 선택된 1종 또는 2종 이상의 추가성분 0.5~20중량부를 더 포함할 수 있다. The composition of the present invention may further comprise 0.5 to 20 parts by weight of one or more additional components selected from green tea extract powder, aloe extract powder, prune concentrated powder and probiotics.
녹차추출물은 본 조성물에서 항산화 작용 등 녹차의 공지된 효과를 나타낼 수 있으며, 특히 체지방을 분해하는 작용을 한다. 녹차추출물 분말은 보다 바람직하게는 본 조성물 중에 2~8 중량부로 포함될 수 있다. The green tea extract may exhibit the known effect of green tea such as antioxidative action in the present composition, and particularly acts to decompose body fat. The green tea extract powder is more preferably contained in the composition in an amount of 2 to 8 parts by weight.
알로에추출물은 본 조성물에서 알로에의 공지된 효과를 나타내며 특히 배변활동에 도움을 줄 수 있다. 알로에추출물 분말은 보다 바람직하게는 본 조성물 중에 0.2~1중량부로 포함될 수 있다. 알로에에 대해 좀 더 자세히 설명하면, 알로에는 백합과(Liliaceae)의 알로에속(Aloinease)에 속하는 다년생 초본의 열대 식물이다. 알로에의 유효 성분은 지금까지 약 200여종이 알려져 있으며, 그 중 안트라퀴논류(anthraquinones)와 다당류가 주요 성분이다. 안트라퀴논류는 알로에 외피 바로 밑에 위치한 유관 속의 유세포에 존재하는 노란색의 즙액(Sap)으로 알로인(aloin)과 알로에에모딘(aloeemodin)이 주성분으로 쓴맛이 나며 타액과 위액의 분비를 촉진하고 건위작용이나 정장작용을 하고 변비개선 효과가 있고 항균 작용도 있는 것으로 보고되고 있다. 다당체인 알로에보란 A는 혈당강하작용이 있고, 알로에 베라 겔은 위산을 중화시켜 주고 위에 포만감을 주는 효과가 있다고 알려져 있다. 또한 알로에의 안트라퀴논류와 폴리페놀 물질들이 가진 수산기에 의한 항산화 작용이 기대되는데 알로인의 페놀산에스터들도 매우 강력한 항산화작용을 갖는 것으로 알려져 있다. 가장 널리 이용되고 있는 알로에 종은 알로에 베라와 알로에 아보레센스이며, 알로에 아보레센스는 쓴맛과 안트라퀴논 물질로 인해 식품으로 한정되어 사용되고 있으나, 알로에 베라는 주스나 겔 타입의 건강기능성 식품으로 널리 사용될 뿐만 아니라 제약이나 화장품에서도 가장 널리 사용되고 있다. The aloe extracts exhibit the known effects of aloe in the present composition and can particularly aid in bowel action. The aloe extract powder is more preferably contained in the composition in an amount of 0.2 to 1 part by weight. Aloe is a perennial herbaceous tropical plant belonging to the genus Aloinease of the Liliaceae . To date, about 200 active ingredients of aloe have been known, of which anthraquinones and polysaccharides are the major components. Anthraquinones are yellow sap which are present in flow cells in the ducts located just below the aloe skin. Aloin and aloeemodin are the main components, and they have a bitter taste. They stimulate secretion of saliva and gastric juice, And has been reported to have an effect of improving the constipation and antimicrobial action. The polysaccharide Aloe Borane A has a hypoglycemic effect, and Aloe Vera gel is said to neutralize the acid and give a feeling of satiety. It is also expected that antioxidative action of aloe's anthraquinones and polyphenol materials is due to the hydroxyl group. Aloe phenolic acid esters are also known to have a very strong antioxidant activity. The most widely used aloe species are aloe vera and aloe avoresense, and aloe avoresense is limited to foods due to bitter taste and anthraquinone substances, but aloe vera is widely used as juice or gel type health functional food It is most widely used in pharmaceuticals and cosmetics.
프룬은 본 조성물에서 프룬의 공지된 효과를 나타내며, 특히 배변을 돕고 맛결정 물질로서 본 조성물의 맛을 좋게 할 수 있다. 프룬농축분말은 보다 바람직하게는 본 조성물 중에 1~3중량부로 포함될 수 있다. Prunes exhibit the known effect of prunes in the present compositions, and can especially aid bowel movements and improve the taste of the present compositions as taste crystals. The prune-concentrated powder is more preferably contained in the composition in an amount of 1 to 3 parts by weight.
프로바이오틱스(probiotics)는 장내 세균을 개선시킬수 있는 생균제를 말하는 것으로 장내 세균의 증식 촉진물질(올리고당 등의 난소화성 탄수화물)을 말하며, 또한 이들의 혼합물을 신바이오틱스(synbiotics) 라고 한다. 본 조성물에서 프로바이오틱스는 보다 바람직하게는 0.2~1중량부로 포함될 수 있다. 본 조성물에 포함되는 프로바이오틱스는, 바람직하게는 스트렙토코커스 서모필러스, 락토바실러스 플라타룸, 락토바실러스 파라카제이, 비피도박테리움 롱검, 락토바실러스 람노수스, 락토바실러스 애시도필러스, 락토바실러스 카제이, 비피도박테리움 브레브, 락토바실러스 퍼멘툼, 비피도박테리움 비피덤, Lactobacillus debruecki sspcbulgaricus. Lactobacillus reuteri 중에서 선택된 1종 또는 2종 이상의 미생물로 이루어진다. 상기 프로바이오틱스는, 특히 바람직하게는 락토바실러스 플라타룸과 락토바실러스 애시도필러스를 포함한다.Probiotics refers to probiotics capable of ameliorating intestinal bacteria and refers to substances that promote the proliferation of intestinal bacteria (ovarian-resistant carbohydrates such as oligosaccharides), and their mixture is called synbiotics. More preferably, the probiotics in the present composition may be contained in an amount of 0.2 to 1 part by weight. The probiotics contained in the present composition are preferably selected from the group consisting of Streptococcus thermophilus, Lactobacillus platarium, Lactobacillus paracasei, Bifidobacterium long sword, Lactobacillus lambatus, Lactobacillus acidophilus, Lactobacillus casei , Bifidobacterium breve, Lactobacillus perfumantum, Bifidobacterium bifidum, Lactobacillus debruecki sspcbulgaricus. Lactobacillus reuteri, and the like. The probiotics particularly preferably comprise Lactobacillus platarium and Lactobacillus acidophilus.
락토바실러스 애시도필러스(Lactobacillus Acidophilus)는 건강한 사람의 장에 존재하는 토착 우점 균종으로 소화관 내의 낮은 pH, 담즙산, 라이소자임(lysozyme)에 대한 저항성이 있고, 장관 상피세포에 흡착할 수 있는 성질 등을 갖고 있어서 소화기관내에서 생존력과 정착성이 우수하고, 특히 회장 말단에서 높은 수준으로 생장한다. 락토바실러스 애시도필러스는 소장에서 유해한 미생물의 장내 정착과 생장 및 대사활성을 조절함으로써 유익한 정상 균총을 유지하도록 할 뿐 아니라 일시적으로 감염된 장내 병원균이 장관, 특히 소장에 정착할 기회를 감소시킨다. Lactobacillus Acidophilus is an indigenous dominant fungus in the intestine of a healthy person. It is resistant to low pH, bile acid and lysozyme in the gastrointestinal tract and can adsorb to the intestinal epithelium. It has excellent survival and fixability in the digestive tract, and grows at a high level especially at the end of the ileum. Lactobacillus ashidophilus not only maintains beneficial normal microflora by controlling intestinal colonization and growth and metabolic activity of harmful microorganisms in the small intestine, but also reduces the chance of temporarily colonizing infected intestinal pathogens in the intestine, especially the small intestine.
락토바실러스 플란타륨(Lactobacillus plantarum)은 장내 병원균 억제, 장내 투과성 감소, 복부 팽만 감소, 면역 체계 강화, 감기 및 독감의 빈도심각도지속기간 감소, 진균 감염 억제, 췌장 폐혈증 감염 억제, HIV 어린이의 면역자극, 수술 후 감염 위험 감소, 외상 환자의 증상 완화, 화상 감염(국소) 억제, 화창 치유 가속화, 폐렴 위험 감소, 염증 반응 감소, 신장 결석 위험 감소, 혈압 감소 등의 효능이 있다. Lactobacillus plantarum inhibits intestinal pathogens, reduces intestinal permeability, reduces abdominal distension, strengthens the immune system, reduces the frequency and severity of flu and flu, suppresses fungal infections, inhibits pancreatic hematopoietic infections, immunologic stimulation of HIV children , Reducing the risk of postoperative infection, relieving symptoms of trauma patients, inhibiting burn infection (locally), accelerating healing of the sun, reducing the risk of pneumonia, reducing the inflammatory response, reducing the risk of kidney stones, and reducing blood pressure.
본 발명의 조성물은, 분말결정포도당, 아밀라아제, 식물성 프로테아제, 효소처리스테비아, 식물성 크림분말 및 말토덱스트린 중에서 선택된 1종 또는 2종 이상의 첨가제 0.5~20중량부를 더 포함할 수 있다. The composition of the present invention may further comprise 0.5 to 20 parts by weight of one or more additives selected from powdered crystalline glucose, amylase, vegetable protease, enzyme-treated stevia, vegetable cream powder and maltodextrin.
스테비아(Stevia rebaudian bertoni)는 브라질과 파라과이에서 야생으로 자라는 국화속 식물로 단맛을 내는 약초이다. 스테비아는 일본, 한국, 중국, 남미에서 주로 이용하며, 음료를 포함하여 과자류, 채소절임, 해산물요리 등 다양한 음식에 약 10여 년간 감미료로 이용되어 오고 있으며 스테비아 추출물은 미국에서 식이보충제로서 광범위하게 이용되고 있다. 스테비아의 주성분은 스테비올(steviol)을 배당체로 하는 스테비오사이드(stevioside)와 레바우디오사이드(Rebaudioside) A, C, D, E이며, 둘코사이드(ducolcoside) A가 미량 존재한다. 스테비오사이드는 저칼로리의 감미료로 자당의 감미증강 및 감미개량제로서의 가치가 인정되고 있으며, 1952년 이래 미국의 NIH(National Institute of Health)에서 새로운 항관절염제 제조원료의 대상으로 연구 중이며, 원산지에서는 저혈당제로서 당뇨병에 이용하고 있다. 마른 스테비아 잎에는 약 5-10중량%의 스테비오사이드가 들어있으며, 감미성분은 설탕의 200-300배 단맛이 더 강하다고 알려져 있다. 스테비아의 추출물에는 스테비오사이드 외에도 다양한 폴리페놀 또한 함유되어 있어 녹차의 20배 이상에 달하는 높은 항산화능을 가지고 있는 것으로 밝혀져 있으며 이외 고지방식이로 인한 체중증가 억제, 체중감소 효과, 혈중 지질 개선, 고지방 섭취로 인한 조직중의 지질 축적 억제, β-산화를 증가시켜 체내 지방축적 감소 등의 효능이 알려져 있다. 효소처리 스테비아는 스테비아추출물에 α-글루코실전이효소 등을 이용하여 글루코오스를 부가시켜 얻어지는 것으로서 그 성분은 α-글루코실스테비오사이드 등이며 이 품목을 건조물로 환산한 것은 스테비올배당체 80.0% 이상을 함유하고 미반응스테비올배당체 15.0% 이하를 함유한다.Stevia (Stevia rebaudian bertoni) is a chrysanthemum that grows wild in Brazil and Paraguay and is a sweet herb. Stevia is mainly used in Japan, Korea, China and South America. It has been used for various foods such as confectionery, pickles and seafood including beverages for about 10 years as a sweetener. Stevia extract is widely used as a dietary supplement in the United States . The main component of stevia is stevioside and rebaudioside A, C, D, E with steviol as glycosides, and ducoloside A is present in trace amounts. Stevioside is a sweetener with low calorie value and is recognized as a sweetener for improving sucrose and sweeteners. Since 1952, the US National Institute of Health (NIH) has been working on a new anti-arthritic raw material, And is used for diabetes. Dried Stevia leaves contain about 5-10 weight percent stevioside, and the sweetness component is said to be 200-300 times more sweet than sugar. In addition to stevioside, stevia extract also contains various polyphenols, which are found to have high antioxidant ability that is more than 20 times that of green tea. In addition, it has been shown that the high fat diet inhibits weight gain, weight loss, , Inhibits lipid accumulation in tissues, increases β-oxidation, and decreases the accumulation of fat in the body. Enzymatic treatment Stevia is obtained by adding glucose to a stevia extract using α-glucosyltransferase or the like, and its component is α-glucosyl stevioside. When it is converted into a dried product, it is considered that the stevia glycoside is more than 80.0% And not more than 15.0% of unreacted steviol glycosides.
본 발명의 조성물은 과립형태의 항산화 및 항비만 제제로 제조할 수 있다. The composition of the present invention can be prepared in granular form in antioxidant and anti-obesity preparations.
먼저, 차전차피 분말 56~60중량부, 흑생강 분말 5중량부 및 기타성분 21~27중량부을 체로 쳐서 균일화한 후 혼합한다. 이때 체는 #40 체를 사용하는 것이 보다 바람직하다. First, 56 to 60 parts by weight of the powdery green tea powder, 5 parts by weight of the black ginger powder and 21 to 27 parts by weight of the other ingredients are sieved, homogenized and mixed. At this time, it is more preferable to use a # 40 sieve.
상기 혼합물에 혼합물 100중량부당 음용수 1~100중량부를 가하여 혼합한다. 이때 음용수는 혼합물을 죽상으로 만들어 과힙화하기 이한 것이므로, 죽상으로 만들기에 필요한 양이면 충분하며, 음용수는 바람직하게는 식수로 사용 가능한 물이다. 1 to 100 parts by weight of drinking water per 100 parts by weight of the mixture is added to the mixture. In this case, since the drinking water is used to make the mixture into a bamboo shape and to be hipped, the amount necessary for making the bamboo is enough, and the drinking water is preferably water that can be used as drinking water.
상기 혼합물을 과립화한다. 이때 1.5mm/#12망의 망규격을 사용한 과립기에서 과립화하는 것이 바람직하다.The mixture is granulated. At this time, granulation is preferably carried out in a granulator using a mesh standard of 1.5 mm / # 12 mesh.
과립화한 후 60±2℃에서 수분함량이 10% 이하가 되도록 건조시켜 과립형 항산화 및 항비만 제제를 제조한다. After granulation, the granules are dried at 60 ± 2 ° C to a moisture content of 10% or less to prepare granular antioxidant and anti-obesity preparations.
상기와 같은 본 발명의 항산화 및 항비만 조성물은 중성의 pH를 가지는 적색이 약간 도는 갈색으로, 폴리페놀 함량, 플라보노이드 함량, DPPH 라디칼 소거활성, ABTS 라디칼 소거활성 및 환원력으로 확인된 항산화효과가 우수하며, 인체에 섭취시켰을 때 체중, 체질량지수, 체지방, 체지방율 및 복부지방율의 감소로 확인된 항비만효과가 우수하다. The antioxidant and anti-obesity composition of the present invention as described above is excellent in antioxidative effect as confirmed by polyphenol content, flavonoid content, DPPH radical scavenging activity, ABTS radical scavenging activity and reducing power, and having a neutral pH and slightly reddish brown , Body weight, body mass index, body fat, body fat percentage, and abdominal fat ratio when administered to human body.
[[ 실시예Example ]]
이하 실시예를 통하여 본 발명을 보다 상세하게 설명한다. 하기 실시예는 본 발명을 예시하는 것으로 본 발명의 범위가 이에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to examples. The following examples illustrate the invention and are not to be construed as limiting the scope of the invention.
<< 실시예Example 1> 1>
차전차피 분말은 인도산으로 식이섬유함량이 88%인 것을 구입하여 사용하였고, 흑생강 분말은 태국산을 구입하여 사용하였다. The tea flour powder was purchased from India with 88% dietary fiber content, and black ginger powder was purchased from Thailand.
차전차피 분말 61g, 흑생강 분말 10g, 녹차추출물분말 5g, 알로에추출물분말 5g, 분말결정포도당 2g, α-아밀라아제 0.5g, 식물성 프로테아제 0.5g, 프룬농축분말 2g, 효소처리스테비아 1g, 프로바이오틱스(12종) 0.5g, 식물성 크림분말 4.5g 및 말토덱스트린 8g을 혼합한 혼합물 24g을 #40 체로 체친 후 혼합기에서 30rpm으로 10분 동안 균질하게 혼합하여 항산화 및 항비만 조성물을 제조하였다. 상기 프로바이오틱스(12종)은 Streptococcus thermophiles, Lactibacillus plantarum, Lactobaillus paracasei, Bifidobacterium longum Lactobacillus rtamnosus, Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium breve, Lactobacillus fermentum, Lactobacillus debruecki sspcbulgaricus, Lactobacillus reuteri, Bifidobacterium bifidum를 포함한다.Amylase 0.5 g, vegetable protease 0.5 g, prune-concentrated powder 2 g, enzyme-treated stevia 1 g, probiotics (12 g), black ginger powder 10 g, green tea extract powder 5 g, aloe extract powder 5 g, powdered crystalline glucose 2 g, ), 4.5 g of vegetable cream powder, and 8 g of maltodextrin were mixed in a # 40 sieve and mixed in a mixer at 30 rpm for 10 minutes to prepare an antioxidant and anti-obesity composition. The probiotics (12 kinds) include Streptococcus thermophiles, Lactibacillus plantarum, Lactobaillus paracasei, Bifidobacterium longum Lactobacillus rtamnosus, Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium breve, Lactobacillus fermentum, Lactobacillus debruecki sspcbulgaricus, Lactobacillus reuteri, Bifidobacterium bifidum.
<< 실시예Example 2> 2>
실시예 1의 조성물에 조성물 100g당 물 15g을 가하여 10분 동안 균질하게 혼합하였다. To the composition of Example 1 was added water And the mixture was uniformly mixed for 10 minutes.
상기 조성물과 음용수의 혼합물을 망규격이 1.5mm/#12망을 사용한 과립기에서 과립화하였다. 과립화한 후 60±2℃에서 수분함량이 10% 이하가 되도록 건조시켜 과립형 항산화 및 항비만 제제를 제조하였다.The mixture of the composition and the drinking water was granulated in a granulator using a mesh size of 1.5 mm / # 12 mesh. Granulated and dried at 60 ± 2 ° C to a moisture content of 10% or less to prepare granular antioxidant and anti-obesity preparations.
제조된 과립형 항산화 및 항비만 제제의 사진을 도 1에 나타내었다. FIG. 1 shows photographs of the prepared granular antioxidant and anti-obesity preparations.
[[ 실험예Experimental Example ]]
실험 시료의 준비Preparation of experimental sample
실험예 1에서는 상기 실시예 1에서 제조한 항산화 및 항비만 조성물에 10배의 증류수를 가하여 실험 시료로 사용하였다. 실험예 2 내지 7에서는 상기 실시예 1에서 제조한 항산화 및 항비만 조성물을 메탄올에 녹인 후 여과하여 실험 시료로 사용하였다.In Experimental Example 1, 10 times of distilled water was added to the antioxidant and anti-obesity composition prepared in Example 1 and used as an experimental sample. In Experimental Examples 2 to 7, the antioxidant and anti-obesity compositions prepared in Example 1 were dissolved in methanol and then filtered to be used as an experimental sample.
<< 실험예Experimental Example 1> 1>
pH와 색도 확인Check pH and color
본 발명의 항산화 및 항비만 조성물의 pH와 색도를 확인하였다., The pH and chromaticity of the antioxidant and anti-obesity compositions of the present invention were determined.
실험 시료에 대하여 pH를 확인한 결과, 7.45±0.02로 중성의 범위를 나타내었다. The pH of the test sample was 7.45 ± 0.02.
실험 시료에 대하여 색도를 측정한 결과, 명도(L)는 33.44±0.59, 적색도(a)는 5.88±0.11, 황색도(b)는 18.14±0.50의 수치를 나타내어 적색이 약간 도는 갈색의 색을 나타내었다(도 1 참조). 이러한 색은 흑생강의 보라빛과 다른 부재료의 색이 혼합된 결과인 것으로 판단된다.The chromaticity of the test sample was 33.44 ± 0.59, 5.88 ± 0.11, and 18.14 ± 0.50, respectively. The color of the sample was slightly reddish brown (See Fig. 1). These colors are considered to be the result of blending the violet of black ginger with the color of other materials.
<< 실험예Experimental Example 2> 2>
폴리페놀 화합물 함량Polyphenol compound content
폴리페놀 화합물은 식물계에 널리 분포하는 2차 대사물질로 수산기를 가지는 방향성 화합물을 총칭하는 것으로서, 수산기를 통한 수소공여와 페놀 고리 구조의 공명 안정화에 의하여 항산화능을 나타낸다. The polyphenol compound is a secondary metabolite widely distributed in the vegetable field. It is a generic term for a directional compound having a hydroxyl group, and exhibits antioxidative ability by hydrogen donation through a hydroxyl group and resonance stabilization of a phenol ring structure.
실험 시료 0.2㎖에 폴린-시오칼토 페놀시약(Folin-Ciocalteu's phenol reagent, Sigma Chemical Co., St. Louis, MO, USA)와 증류수를 1:2로 섞은 혼합액 0.2㎖를 첨가하여 실온에서 3분간 방치한 후 10% 탄산나트륨(sodium carbonate, Na2CO3)(Samchun Pure Chemical Co., Ltd., Pyeongtaek, Korea) 3㎖를 가하여 1시간 동안 암실에서 반응시킨 뒤 765nm에서 흡광도를 측정하였다. To 0.2 ml of the test sample, 0.2 ml of a mixture of a 1: 2 mixture of distilled water and a Folin-Ciocalteu's phenol reagent (Sigma Chemical Co., St. Louis, Mo., USA) was added and left at room temperature for 3 minutes After 3 ml of 10% sodium carbonate (Na 2 CO 3 ) (Samchun Pure Chemical Co., Ltd., Pyeongtaek, Korea) was added, the reaction was allowed to proceed for 1 hour in a dark room and absorbance was measured at 765 nm.
갈산(Gallic acid)을 이용하여 얻은 표준곡선(standard curve)의 검량식에 흡광도를 적용하여 이 검량곡선으로부터 시료 중의 총 폴리페놀 함량을 구하였다.The absorbance was applied to the calibration equation of a standard curve obtained using gallic acid, and the total polyphenol content in the sample was determined from this calibration curve.
그 결과, 실험 시료 중의 총 페놀 화합물의 함량은 425.95±28.91mg/100g GAE로 확인되었다.As a result, the content of total phenolic compounds in the test sample was 425.95 ± 28.91 mg / 100 g GAE.
<< 실험예Experimental Example 3> 3>
플라보노이드 화합물 함량Flavonoid compound content
본 발명의 항산화 및 항비만 조성물의 총 플라보노이드 화합물 함량을 다음과 같이 측정하였다.The total flavonoid compound content of the antioxidant and anti-obesity compositions of the present invention was determined as follows.
플라보노이드는 폴리페놀에 속하는 성분으로 노란색 혹은 담황색을 나타내는 페놀계 화합물을 총칭하는 것으로 채소류와 식품의 잎, 꽃, 과실,줄기 및 뿌리 등의 자연계에 널리 분포하며, 항산화, 항암, 심장질환 예방 효과 등 다양한 생리활성을 가지고 있는 것으로 보고되고 있다. Flavonoid is a component belonging to polyphenol and refers to a phenol compound which shows yellow or light yellow color. It is widely distributed in vegetables such as leaves, flowers, fruits, stems and roots of vegetables and antioxidant, anti-cancer, Have been reported to have various physiological activities.
실험 시료 1.25㎖에 5% 질산나트륨(sodium nitrite, NaNO2)(Samchun Pure Chemical Co., Ltd.) 75㎕를 넣고 5분간 방치한 후 10% 염화알루미늄 6수화물(Aluminium Chloride Hexahydrate, AlCl3·6H2O)(Junsei Chemical Co., Ltd., Nihonbashi-Honcho, Japan) 150㎕를 넣고 6분간 방치하였다. 그 다음 1M 수산화나트륨(NaOH)(Samchun Pure Chemical Co., Ltd.,) 500㎕를 가하여 11분 후 510nm에서 흡광도를 측정하였다. Experimental samples 1.25㎖ 5% sodium nitrite (sodium nitrite, NaNO 2) ( Samchun Pure Chemical Co., Ltd.) into a 75㎕ 10% above and allowed to stand for 5 minutes to aluminum chloride hexahydrate (Aluminium Chloride Hexahydrate, AlCl 3 · 6H 2 O) (Junsei Chemical Co., Ltd., Nihonbashi-Honcho, Japan) was added and left for 6 minutes. Then, 500 μl of 1 M sodium hydroxide (NaOH) (Samchun Pure Chemical Co., Ltd.) was added, and the absorbance was measured at 510 nm after 11 minutes.
총 플라보노이드 화합물의 함량은 퀘르세틴(quercetin)을 표준물질로 사용하여 얻은 표준곡선의 검량식에 흡광도를 적용하여 구하였다.The content of total flavonoid compounds was determined by applying absorbance to a calibration equation of a standard curve obtained by using quercetin as a standard substance.
그 결과, 실험 시료의 총 플라보노이드 화합물의 함량은 305.19±37.72mg/100g CE이었다. As a result, the content of total flavonoid compounds in the test sample was 305.19 ± 37.72 mg / 100 g CE.
이러한 플라보노이드 화합물은 흑생강에서 유래한 플라보노이드 화합물인 폴리메톡시플라본으로 5,7-디메톡시플라본, 5,7,4'-트리메톡시플라본, 5,7,3',4'-테트라메톡시플라본, 5-하이드록시-7-메톡시플라본, 5-하이드록시-7,4'-디메톡시플라본, 5-하이드록시-3,7-디메톡시플라본, 5-하이드록시-3,7,4'-트리메톡시플라본, 5-하이드록시-3,7,3',4'-테트라메톡시플라본, 3,5,7-트리메톡시플라본, 3,5,7,4'-테트라메톡시플라본, 3,5,7,3',4'-펜타메톡시플라본 등에 의한 것으로 판단된다. These flavonoid compounds are polymethoxy flavone, which is a flavonoid compound derived from black ginger, and is composed of 5,7-dimethoxy flavone, 5,7,4'-trimethoxy flavone, 5,7,3 ', 4'-tetramethoxy Hydroxy-7,7-dimethoxy flavone, 5-hydroxy-7-methoxy flavone, 5-hydroxy-7,4'-dimethoxy flavone, '-Trimethoxy flavone, 5-hydroxy-3,7,3', 4'-tetramethoxy flavone, 3,5,7-trimethoxy flavone, 3,5,7,4'-tetramethoxy Flavone, 3,5,7,3 ', 4'-pentamethoxy flavone, and the like.
<< 실험예Experimental Example 4> 4>
DPPHDPPH 라디칼Radical 소거 활성 Scavenging activity
본 발명의 항산화 및 항비만 조성물의 DPPH 라디칼 소거 활성을 다음과 같이 측정하였다.The DPPH radical scavenging activity of the antioxidant and anti-obesity compositions of the present invention was measured as follows.
DPPH 라디칼 소거 활성은 항산화 물질로부터 유리라디칼에 전자를 공여하여 지방질의 산화를 억제하는 척도로 사용되고 인체 내에서 유리라디칼에 의한 노화를 억제하는 작용의 척도로 이용되고 있다. DPPH radical scavenging activity is used as a measure to inhibit the oxidation of lipids by donating electrons to free radicals from antioxidants and is used as a measure for inhibiting free radical aging in the human body.
DPPH(2,2-diphenyl-1-picrylhydrazyl) 라디칼 소거 활성은 실험 시료 0.1㎖에 0.2mM DPPH(Sigma Chemical Co.) 용액 0.1㎖를 가하여 보텍스 혼합(vortex mixing) 후 암실에서 30분간 반응시켜 517nm에서 흡광도를 측정하였다. 시료 무첨가구는 시료를 처리하지 않고 시료 희석 용매인 증류수를 첨가한 것으로, 동일한 방법으로 흡광도를 측정하였다.DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging activity was determined by adding 0.1 ml of 0.2 mM DPPH (Sigma Chemical Co.) solution to 0.1 ml of the test sample, vortexing the mixture, reacting in a dark room for 30 minutes, Absorbance was measured. The absorbance of the sample without addition of distilled water as a sample diluting solvent was measured in the same manner.
DPPH 라디칼 소거 활성은 하기 수학식 1에 따라 백분율로 나타낸 후 50%의 소거능을 나타내는 시료 농도인 IC50(50% inhibitory concentration) 값을 구하였다.The DPPH radical scavenging activity was expressed as a percentage in accordance with the following formula (1), and then the IC 50 (50% inhibitory concentration), which is a sample concentration exhibiting a scavenging ability of 50%, was determined.
실험 시료의 DPPH 라디칼 소거활성은 IC50값으로 64.01±2.90mg/㎖의 활성을 나타내어 비교적 높은 항산화활성을 나타내는 것으로 확인되었다. The DPPH radical scavenging activity of the test sample was 64.01 ± 2.90 mg / ㎖, which is an IC 50 value, indicating a relatively high antioxidative activity.
<< 실험예Experimental Example 5> 5>
ABTSABTS 라디칼 소거활성 Radical scavenging activity
본 발명의 항산화 및 항비만 조성물의 DPPH 라디칼 소거 활성을 ABTS 라디칼 소거법으로 다음과 같이 확인하엿따.The DPPH radical scavenging activity of the antioxidant and anti-obesity compositions of the present invention was determined by the ABTS radical scavenging method as follows.
ABTS[2,2’-azinobis(3-ethylbenzothiazoline-6-sulfonic acid)] 라디칼 소거 활성은 증류수 5㎖에 140mM 과황화칼륨(potassuim persulfate, K2S2O8)(Samchun) 88㎕를 가하여 혼합 시약을 제조한 후, 이 혼합 시약에 ABTS 디암모늄염 타블렛(diammonium salt tablet)(Sigma) 2알을 넣어 7mM ABTS 수용액을 만들어 암실에 14~16시간 방치하였다. 방치 후, 이를 에탄올과 1:88의 비율로 섞어 734nm에서 측정한 흡광도 값이 0.70±0.02가 되도록 조절한 ABTS 용액을 시약으로 사용하였다. The radical scavenging activity of ABTS [2,2'-azinobis (3-ethylbenzothiazoline-6-sulfonic acid)] was determined by adding 140 mM of potassium persulfate (K 2 S 2 O 8 ) (Samchun) After preparing the reagents, 2 ABTS diammonium salt tablets (Sigma) were added to the mixed reagents, and 7 mM ABTS aqueous solution was prepared and left in the dark room for 14 to 16 hours. After incubation, the mixture was mixed with ethanol at a ratio of 1:88, and the ABTS solution adjusted to have an absorbance value of 0.70 ± 0.02 measured at 734 nm was used as a reagent.
실험 시료 50㎕에 ABTS 용액 1㎖을 가해 10초 동안 보텍스 혼합기(vortex mixer)(Scientific Industries Inc., NY, USA)에서 혼합한 후 2분 30초간 인큐베이션(incubation)하여 734nm에서 반응액의 흡광도를 측정하였다. 1 ml of ABTS solution was added to 50 μl of the test sample, mixed in a vortex mixer (Scientific Industries Inc., NY, USA) for 10 seconds, incubated for 2 minutes and 30 seconds, and absorbance of the reaction solution was measured at 734 nm Respectively.
시료 무첨가구는 시료를 처리하지 않고 시료 희석 용매인 증류수를 첨가한 것을 동일한 방법으로 흡광도를 측정하였다. Absorbance was measured by the same method as in the case of adding no distilled water as a sample diluting solvent without sample treatment.
ABTS 라디칼 소거 활성은 하기 수학식 2에 따라 백분율로 나타낸 후 50%의 소거능을 나타내는 시료 농도인 IC50(Inhibitory concentration)값을 구하였다.The ABTS radical scavenging activity was expressed as a percentage according to the following equation (2), and then the IC 50 (inhibitory concentration) value, which indicates a scavenging ability of 50%, was obtained.
실험 시료의 ABTS 라디칼 소거활성은 IC50값으로 4.59±0.25mg/㎖의 활성을 나타내어 높은 항산화활성을 나타내는 것으로 확인되었다. The ABTS radical scavenging activity of the test sample was 4.59 ± 0.25 mg / ㎖, which is an IC 50 value, indicating high antioxidative activity.
<< 실험예Experimental Example 6> 6>
환원력 확인Confirm Reduction Power
본 발명의 항산화 및 항비만 조성물의 환원력을 FRAP 활성으로 다음과 같이 측정하였다.The reducing power of the antioxidant and anti-obesity composition of the present invention was measured as FRAP activity as follows.
FRAP(ferric reducing antioxidant power)는 산성 pH에서 환원제에 의해 Fe3+-TPTZ(ferric tripyridyltriazine) 복합체가 Fe2 +-TPTZ(ferrous tripyridyltriazine)으로 환원되는 원리를 이용한 것으로 시료 중 항산화 물질의 함량에 대한 의존도가 높은 것으로 알려져 있다. FRAP (ferric reducing antioxidant power) is based on the principle that the Fe 3+ -TPTZ (ferric tripyridyltriazine) complex is reduced to Fe 2 + -TPTZ (ferrous tripyridyltriazine) by a reducing agent at acidic pH and its dependence on the content of antioxidants Is known to be high.
FRAP(ferric reducing antioxidant power) 활성은 미리 제조된 아세테이트 버퍼(acetate buffer), TPTZ 용액 및 염화제2철 용액(ferric chloride solution)을 각각 10:1:1(v/v/v)의 비율로 혼합하여 37℃에서 10분간 인큐베이션하여 FRAP 시약을 준비하였다.The ferric reducing antioxidant power (FRAP) activity was measured by mixing the previously prepared acetate buffer, TPTZ solution and ferric chloride solution at a ratio of 10: 1: 1 (v / v / v) And incubated at 37 DEG C for 10 minutes to prepare an FRAP reagent.
실험 시료 30㎕에 FRAP 시약 900㎕와 증류수 90㎕를 가하여 보텍스 혼합기로 혼합한 후 37℃에서 10분간 방치한 뒤 593nm에서 흡광도를 측정하였다.900 μl of FRAP reagent and 90 μl of distilled water were added to 30 μl of the test sample, mixed with a vortex mixer, allowed to stand at 37 ° C for 10 minutes, and the absorbance was measured at 593 nm.
FRAP 값은 황산제1철 6수화물(iron sulfate hexahydrate, FeSO4·6H2O)을 표준물질로 사용하여 얻은 표준곡선의 검량식에 흡광도를 적용하여 구했으며, 시료 1g에 들어있는 황산제1철 6수화물의 mM 함량으로 나타내었다.The FRAP value was obtained by applying the absorbance to the calibration equation of a standard curve obtained by using iron sulfate hexahydrate (FeSO 4 .6H 2 O) as a standard material. The ferrous sulfate contained in 1 g of the sample MM hexahydrate.
실험 시료의 FRAP 활성은 시료 1g에 대한 mM로 환산하여 계산하였을 때 60.14±2.49mM의 활성을 나타내었다. The FRAP activity of the test sample was 60.14 ± 2.49 mM when calculated as 1 mM of the sample.
상기 결과들을 하기 표 1에 나타내었다.The results are shown in Table 1 below.
a 5.88 ±0.11
b 18.14 ±0.50L 33.44 + - 0.59
a 5.88 + - 0.11
b 18.14 + - 0.50
상기 표 1에서와 같이, 본 발명의 항산화 및 항비만 조성물은 라디칼 소거활성에 의한 항산화 활성뿐 아니라 환원력에 의한 항산화 활성도 높은 것으로 확인되어 항산화, 항암, 항균, 당뇨병, 심장질환 등 활성산소에 노출되어 손상되는 DNA의 보호나 세포의 구성물질인 단백질 및 효소를 보호하는 항산화 능력이 커서 암을 비롯한 다양한 질병에 위험도를 낮춰주는 역할을 할 수 있을 것이라 판단된다. As shown in Table 1, the antioxidant and anti-obesity compositions of the present invention were found to have high antioxidative activity by reducing power as well as antioxidative activity by radical scavenging activity, and were exposed to active oxygen such as antioxidant, anticancer, antibiotic, diabetes, The antioxidant capacity to protect the damaged DNA and the proteins and enzymes that constitute the cell is high, and it is considered that it can play a role of lowering the risk to various diseases including cancer.
<< 실험예Experimental Example 7> 7>
항비만Anti-obesity 효과 effect
본 발명의 항산화 및 항비만 조성물의 항비만 효과를 다음과 같이 실험하였다.The anti-obesity effect of the antioxidant and anti-obesity composition of the present invention was tested as follows.
실험은 대전 지역에 거주하고 있으며 일상식이를 하는 20~50대의 남녀 26명을 대상으로 실시예 2의 제제를 30일간 매회 1회씩 6g씩 2회 섭취시켰다. The experiment was conducted on 26 men and women aged 20 ~ 50 who live in Daejeon area and took the preparation of example 2 twice for 6 days each once for 30 days.
실험에 참가한 참가자들의 겨우 다이어트 식품 및 약을 먹어본 경험이 44%였고 참가자들의 88.9%가 아침식사를 하는 것으로 조사되었다. Only 44% of participants in the experiment had experience of eating diet and medicine, and 88.9% of the participants were eating breakfast.
다이어트를 하는 목적으로는 참가자 중 61.1%가 건강해지기 위해서라고 응답하고, 38.9%가 외모를 위해서라고 응답하여, 다이어트를 건강과 관련지어 생각하는 것으로 확인되었다. For the purpose of diet, 61.1% of participants answered that they want to be healthy, and 38.9% answered that they are for appearance, and it was confirmed that they think diet related to health.
또한 다이어트 성공을 위해서 참가자의 66.7%가 운동, 식이 및 약물 요법을 병행하는 것을 원하는 것으로 조사되어 운동 및 식이요법 외에 다이어트 보조방법으로 약물이나 다이어트 식품을 필요로 하는 것으로 조사되었다. In addition, 66.7% of the participants wanted exercise, diet, and medication in order to succeed in the diet, and they needed drugs or diet foods in addition to exercise and diet.
실시예 2의 제제에 대한 기호도 조사 결과 섭취시 물을 많이 섭취해야 하는 불편함 외에 제제의 성상이나 맛에 대해서는 전반적으로 만족하는 것으로 조사되었다. As a result of the preference test for the preparation of Example 2, it was found that the composition and taste of the preparation were generally satisfactory in addition to the inconvenience of consuming a lot of water at the time of ingestion.
섭취 전 및 섭취 후 인바디 체성분 측정기를 사용하여 신체의 체중, 체질량지수(BMI), 체지방, 체지방률, 복부지방률을 측정하여 결과를 하기 표 2에 나타내었다. Body weight, body mass index (BMI), body fat, body fat percentage, and abdominal fat percentage were measured using an inborn body composition measuring device before and after ingestion, and the results are shown in Table 2 below.
(n=26)Before ingestion (B)
(n = 26)
(n=26)After ingestion (A)
(n = 26)
N.S.는 paired t-test 결과 유의적인 차이가 없음을 의미한다.
*는 paired t-test 결과 p<0.05 수준에서 유의적인 차이가 있음을 의미한다.
WHR : Waist Hip Ratio
BMI : Body Mass Index = body weight(kg)/{height(m2)}Values are mean ± standard deviation.
NS means no significant difference in paired t-test results.
* Indicates a significant difference at the p <0.05 level in paired t-test results.
WHR: Waist Hip Ratio
BMI: Body Mass Index = body weight (kg) / {height (m 2 )}
상기 표 2의 결과에서와 같이, 본 발명의 제제를 섭취한 후 체중, 체질량지수, 체지방, 체지방률 및 복부지방률이 유의적으로 감소하였으며(p<0.05), 체중은 섭취 후 평균 약 2.92kg 감소한 것으로 확인되었다. As shown in the results of Table 2, weight, body mass index, body fat, body fat percentage and abdominal fat ratio were significantly decreased (p <0.05) after ingestion of the preparation of the present invention, and body weight was decreased by about 2.92 kg Respectively.
Claims (8)
차전차피 분말 55~65중량부 및 흑생강 분말 7~14중량부를 포함하는 것을 특징으로 하는 항산화 및 항비만 조성물.The method according to claim 1,
55 to 65 parts by weight of a tea tank powder and 7 to 14 parts by weight of a black ginger powder.
상기 차전차피 분말은 식이섬유의 함량이 80% 이상인 것을 특징으로 하는 항산화 및 항비만 조성물.The method according to claim 1,
Wherein said tea powder powder has a dietary fiber content of 80% or more.
상기 조성물은, 녹차추출물 분말, 알로에추출물 분말, 프룬농축분말, 프로바이오틱스 중에서 선택된 1종 또는 2종 이상의 추가성분 0.5~20중량부를 더 포함하는 것을 특징으로 하는 항산화 및 항비만 조성물.The method according to claim 1,
Wherein the composition further comprises 0.5 to 20 parts by weight of one or more additional components selected from green tea extract powder, aloe extract powder, prune concentrated powder and probiotics.
상기 조성물은, 분말결정포도당, 아밀라아제, 식물성 프로테아제, 효소처리스테비아, 식물성 크림분말 및 말토덱스트린 중에서 선택된 1종 또는 2종 이상의 첨가제 0.5~20중량부를 더 포함하는 것을 특징으로 하는 항산화 및 항비만 조성물.The method according to claim 1,
Wherein the composition further comprises 0.5 to 20 parts by weight of one or more additives selected from powdered crystalline glucose, amylase, vegetable protease, enzyme-treated stevia, vegetable cream powder and maltodextrin.
상기 프로바이오틱스는, 스트렙토코커스 서모필러스, 락토바실러스 플라타룸, 락토바실러스 파라카제이, 비피도박테리움 롱검, 락토바실러스 람노수스, 락토바실러스 애시도필러스, 락토바실러스 카제이, 비피도박테리움 브레브, 락토바실러스 퍼멘툼, 비피도박테리움 비피덤, Lactobacillus debruecki sspcbulgaricus. Lactobacillus reuteri 중에서 선택된 1종 또는 2종 이상의 미생물로 이루어진 것을 특징으로 하는 항산화 및 항비만 조성물.5. The method of claim 4,
The probiotics may be selected from the group consisting of Streptococcus thermophilus, Lactobacillus platarium, Lactobacillus paracasei, Bifidobacterium longum, Lactobacillus lambatus, Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium breve , Lactobacillus perfumantum, Bifidobacterium bifidum, Lactobacillus debruecki sspcbulgaricus. Lactobacillus reuteri. ≪ RTI ID = 0.0 > 1. < / RTI >
상기 균일화된 각 원료를 혼합하는 단계;
상기 원료의 혼합물에 혼합물 100중량부 당 음용수 1~100 중량부를 가하여 혼합하는 단계;
상기 원료와 음용수의 혼합물을 과립화하는 단계; 및
상기 과립을 60±2℃에서 수분함량이 10% 이하가 되도록 건조시키는 단계를 포함하는 과립형 항산화 및 항비만 제제의 제조방법.(a) an active ingredient comprising 50 to 70 parts by weight of the powdery powder and 5 to 20 parts by weight of black ginger powder; (b) a green tea extract powder; Aloe extract powder; Prune-concentrated powder; 0.5 to 20 parts by weight of one or more additional components selected from probiotics and (c) one or more additives selected from powdered crystalline glucose, amylase, vegetable protease, enzyme-treated stevia, vegetable cream powder and maltodextrin 0.5 To 20 parts by weight of a raw material;
Mixing each of the homogenized raw materials;
Adding 1 to 100 parts by weight of drinking water per 100 parts by weight of the mixture to the mixture of the raw materials;
Granulating a mixture of the raw material and the drinking water; And
And drying the granules at a temperature of 60 占 폚 to a water content of 10% or less at 60 占 占 폚.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180007205A KR102132066B1 (en) | 2018-01-19 | 2018-01-19 | Antioxidant and anti-Obesity composition comprising Psyllium Husk and Kaempferia parviflora, formulatiom using the composition and preparing method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180007205A KR102132066B1 (en) | 2018-01-19 | 2018-01-19 | Antioxidant and anti-Obesity composition comprising Psyllium Husk and Kaempferia parviflora, formulatiom using the composition and preparing method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20190088740A true KR20190088740A (en) | 2019-07-29 |
KR102132066B1 KR102132066B1 (en) | 2020-07-08 |
Family
ID=67480892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180007205A Active KR102132066B1 (en) | 2018-01-19 | 2018-01-19 | Antioxidant and anti-Obesity composition comprising Psyllium Husk and Kaempferia parviflora, formulatiom using the composition and preparing method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102132066B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021057099A1 (en) * | 2019-09-27 | 2021-04-01 | 高美雯 | Plantago ovata and konjak chips and preparation method therefor |
KR20210100300A (en) | 2020-02-06 | 2021-08-17 | 대한민국(산림청 국립산림과학원장) | Composition for Anti obesity comprising extract of Sageretia thea fruits |
KR102794048B1 (en) | 2024-07-04 | 2025-05-16 | 한방바이오 주식회사 | Composition for reducing body fat or anti obesity comprising Stauntonia hexaphylla extract and method of manufacturing the same |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102485676B1 (en) | 2020-08-28 | 2023-01-06 | 선문대학교 산학협력단 | A composition for improving, preventing and treating of obesity comprising Ulva pertusa Kjellman extracts |
KR102619375B1 (en) | 2020-11-26 | 2024-01-02 | (주)휴에버그린팜 | A composition for improving, preventing and treating of obesity comprising Centella asiatica fermentation extract |
KR102687978B1 (en) | 2021-10-13 | 2024-07-25 | 선문대학교 산학협력단 | A composition for improving, preventing and treating of obesity comprising peanut shell extract |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030021215A (en) * | 2003-02-12 | 2003-03-12 | 주식회사 아미노젠 | Anti-obesity constituents contained natural dietary fiber and functional ingredient, and dietary supplementation food made by using it as the effective component. |
KR100504124B1 (en) | 2001-05-18 | 2005-07-27 | 한국 한의학 연구원 | Mixture for prevention of obesity |
KR100562467B1 (en) | 2003-07-18 | 2006-03-17 | 주식회사 싸이클로젠 | Anti-obesity drugs |
JP2009051790A (en) * | 2007-08-29 | 2009-03-12 | Maruzen Pharmaceut Co Ltd | Antioxidant, anti-aging agent, anti-inflammatory agent, hair restoration agent, anti-obesity agent, skin-lightening agent, cosmetic and food and drink for cosmetic use |
KR101488612B1 (en) | 2013-08-12 | 2015-01-30 | 주식회사 엘지생활건강 | A health food and pharmaceutical composition comprising black food ingredients |
KR101672199B1 (en) | 2015-01-23 | 2016-11-04 | 이동찬 | Food composition for preventing or improving obesity comprising mixture of garcinia cambogia and alginic acid and manufacturing method thereof |
-
2018
- 2018-01-19 KR KR1020180007205A patent/KR102132066B1/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100504124B1 (en) | 2001-05-18 | 2005-07-27 | 한국 한의학 연구원 | Mixture for prevention of obesity |
KR20030021215A (en) * | 2003-02-12 | 2003-03-12 | 주식회사 아미노젠 | Anti-obesity constituents contained natural dietary fiber and functional ingredient, and dietary supplementation food made by using it as the effective component. |
KR100562467B1 (en) | 2003-07-18 | 2006-03-17 | 주식회사 싸이클로젠 | Anti-obesity drugs |
JP2009051790A (en) * | 2007-08-29 | 2009-03-12 | Maruzen Pharmaceut Co Ltd | Antioxidant, anti-aging agent, anti-inflammatory agent, hair restoration agent, anti-obesity agent, skin-lightening agent, cosmetic and food and drink for cosmetic use |
KR101488612B1 (en) | 2013-08-12 | 2015-01-30 | 주식회사 엘지생활건강 | A health food and pharmaceutical composition comprising black food ingredients |
KR101672199B1 (en) | 2015-01-23 | 2016-11-04 | 이동찬 | Food composition for preventing or improving obesity comprising mixture of garcinia cambogia and alginic acid and manufacturing method thereof |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021057099A1 (en) * | 2019-09-27 | 2021-04-01 | 高美雯 | Plantago ovata and konjak chips and preparation method therefor |
KR20210100300A (en) | 2020-02-06 | 2021-08-17 | 대한민국(산림청 국립산림과학원장) | Composition for Anti obesity comprising extract of Sageretia thea fruits |
KR102794048B1 (en) | 2024-07-04 | 2025-05-16 | 한방바이오 주식회사 | Composition for reducing body fat or anti obesity comprising Stauntonia hexaphylla extract and method of manufacturing the same |
Also Published As
Publication number | Publication date |
---|---|
KR102132066B1 (en) | 2020-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102132066B1 (en) | Antioxidant and anti-Obesity composition comprising Psyllium Husk and Kaempferia parviflora, formulatiom using the composition and preparing method thereof | |
Al-Snafi | A review on Fagopyrum esculentum: A potential medicinal plant | |
WO2010123037A1 (en) | Agent for regulating composition ratio of intestinal bacterial flora | |
JP2015127340A (en) | Intestinal flora composition ratio regulator | |
JP2010077039A (en) | Immunostimulator or antiallergic agent | |
KR101217080B1 (en) | Composition having herb extract as active incredient for treating hangover and preparation method thereof | |
CN101766274A (en) | Antioxidant functional food composition containing bamboo-leaves flavones | |
WO2017159679A1 (en) | Polysaccharide digestion inhibitor | |
JP4538338B2 (en) | β-glucuronidase inhibitor | |
JP2010254594A (en) | Intestinal Bacteroides growth promoter | |
KR20170086198A (en) | Manufacturing method of diet solid tea including fermentation herb remedy and dietary fiber and the solid tea produced thereby | |
KR100549089B1 (en) | Health functional food for improving bowel function and constipation disease | |
JP2008007473A (en) | Cassia obtusifolia l. or cassia tora l. seed extract | |
KR20200046959A (en) | Health functional food composition for prevention of diabetes | |
KR102133473B1 (en) | A composition as a prebiotic for improving intestinal microflora containing sweet potato vines | |
KR20210085665A (en) | Health promotion composition containing Plantago Seed | |
KR20220057669A (en) | Compositions for Anti-Bacterial and Anti-Inflammatory Effect Comprising Oil of Ulvoid green algae | |
KR20210050432A (en) | Pharmaceutical composition comprising fermentation product of Citrus onshiu | |
KR102838142B1 (en) | Composition for Improving Defecation and Cleansing in the Body Comprising Complex Extract Fermented with Novel Lactic Acid Bacteria as Active Ingredient | |
KR102661369B1 (en) | A functional food composition for preventing and relieving hangover enriched with steamed and lyophilized mature silkworm | |
JP2004256522A (en) | Composition for treating or preventing diabetes | |
JP2014080448A (en) | Agent for promoting proliferation of bacteroides in intestine | |
TWI832945B (en) | Composition for suppressing increase in blood glucose level and suppressing increase in blood triglyceride | |
JP2006219376A (en) | Urease inhibitor | |
JP2010100576A (en) | Constipation-improving agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20180119 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20191008 Patent event code: PE09021S01D |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20200318 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20200701 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20200702 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20200702 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20230628 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20240425 Start annual number: 5 End annual number: 5 |